Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2

References

[1] Gaziano JM. Global burden of cardiovascular disease. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a textbook of cardiovascular medicine 6th edition. Philadelphia: WB Saunders Company; 2001:1–17.10.1016/B978-1-4377-0398-6.00001-9Suche in Google Scholar

[2] Adams III JE, Bodor GS, Dávila-Román V, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 1993;88:101–6.10.1161/01.CIR.88.1.101Suche in Google Scholar PubMed

[3] Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med. 2000;343:1139–47.10.1056/NEJM200010193431602Suche in Google Scholar PubMed

[4] Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58:257–66.10.1373/clinchem.2011.173369Suche in Google Scholar PubMed PubMed Central

[5] Pascual-Figal DA, Januzzi JL. The biology of ST2: The International ST2 Consensus Panel. Am J Cardiol. 2015;115:3B–7B.10.1016/j.amjcard.2015.01.034Suche in Google Scholar PubMed

[6] Lepojärvi ES, Piira O-P, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200.10.3389/fphys.2015.00200Suche in Google Scholar PubMed PubMed Central

[7] Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–6.10.1161/01.CIR.0000038705.69871.D9Suche in Google Scholar PubMed PubMed Central

[8] Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259–67.10.1016/j.amjcard.2010.09.011Suche in Google Scholar PubMed PubMed Central

[9] Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010;159:788–94.10.1016/j.ahj.2010.02.022Suche in Google Scholar PubMed

[10] Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–67.10.1016/S0894-7317(89)80014-8Suche in Google Scholar

[11] Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457–64.10.1016/0002-9149(67)90023-9Suche in Google Scholar PubMed

[12] Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, et al. Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction. World Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol. 2011;40:139–46.10.1093/ije/dyq165Suche in Google Scholar PubMed

[13] Tsai IT, Wang CP, Lu YC, Wu CC, Lu LF, Chung FM, et al. The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovasc Disord. 2017;17:110.1186/s12872-016-0436-7Suche in Google Scholar PubMed PubMed Central

[14] Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW. Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean population. J Am Heart Assoc. 2019;8:e010541.10.1161/JAHA.118.010541Suche in Google Scholar PubMed PubMed Central

[15] Akgul O, Baycan OF, Bulut U, Somuncu MU, Pusuroglu H, Ozyilmaz S, et al. Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26:592–7.10.1097/MCA.0000000000000280Suche in Google Scholar PubMed

[16] Vasile VC, Jaffe AS. Emerging biomarkers for acute heart conditions. Curr Opin Cardiol. 2014;29:312–8.10.1097/HCO.0000000000000077Suche in Google Scholar PubMed

[17] Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol. 2010;185:5743–50.10.4049/jimmunol.0903818Suche in Google Scholar PubMed

[18] Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684–91.10.1161/CIRCHEARTFAILURE.109.873240Suche in Google Scholar PubMed

[19] Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936–44.10.1161/CIRCULATIONAHA.107.728022Suche in Google Scholar PubMed PubMed Central

[20] Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT proBNP. Am Heart J 2011;161:1163–70.10.1016/j.ahj.2011.03.025Suche in Google Scholar PubMed

[21] Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann Emerg Med. 2007;50:153–8.10.1016/j.annemergmed.2007.02.015Suche in Google Scholar PubMed

[22] Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol. 2013;167:2182–8.10.1016/j.ijcard.2012.05.073Suche in Google Scholar PubMed

[23] Sanchez-Mas J, Lax A, Asensio-Lopez C, Fernandez-Del Palacio MJ, Caballero L, Santarelli G, et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest. 2014;44:643–51.10.1111/eci.12282Suche in Google Scholar PubMed

[24] Díez J, Bayes-Genis A. Compelling benefit of soluble suppression of tumorigenicity-2 in post-myocardial infarction estimation of risk: The time is right for its routine use in the clinic. J Am Heart Assoc. 2017;6:e00766510.1161/JAHA.117.007665Suche in Google Scholar PubMed PubMed Central

[25] Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–90.10.1161/01.CIR.0000127958.21003.5ASuche in Google Scholar PubMed

[26] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52.10.1161/CIR.0b013e31829e8807Suche in Google Scholar PubMed

[27] O’Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, et al. Multimarker risk stratification in patients with acute myocardial infarction. J Am Heart Assoc. 2016;5:e002586.10.1161/JAHA.115.002586Suche in Google Scholar PubMed PubMed Central

[28] Wang YP, Wang JH, Wang XL, Liu JY, Jiang FY, Huang XL, et al. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. J Cell Mol Med. 2017;21:2677–84.10.1111/jcmm.13183Suche in Google Scholar PubMed PubMed Central

[29] Yu J, Oh PC, Kim M, Moon J, Park YM, Lee K, et al. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS One. 2017;12:e0182829.10.1371/journal.pone.0182829Suche in Google Scholar PubMed PubMed Central

[30] Liu X, Hu Y, Huang W, Zhang G, Cao S, Yan X, et al. Soluble st2 for prediction of clinical outcomes in patients with st-segment elevation myocardial infarction receiving primary. PCI Int Heart J. 2019;60:19–26.10.1536/ihj.18-020Suche in Google Scholar PubMed

[31] Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80:15L–25L.10.1016/S0002-9149(97)00845-XSuche in Google Scholar

[32] Weir RA, Millar AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243–50.10.1016/j.jacc.2009.08.047Suche in Google Scholar PubMed

[33] Tominaga Si, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun. 1999;264:14–8.10.1006/bbrc.1999.1469Suche in Google Scholar PubMed

[34] Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi Jr JL. Soluble concentrations of the interleukin receptor family member ST2 and ß-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6:1206–13.10.1161/CIRCHEARTFAILURE.113.000457Suche in Google Scholar PubMed

[35] Huang WP, Zheng X, He L, Su X, Liu CW, Wu MX. Role of soluble ST2 levels and betablockers dosage on cardiovascular events of patients with unselected ST-segment elevation myocardial infarction. Chin Med J (Engl). 2018;131:1282–88.10.4103/0366-6999.232819Suche in Google Scholar PubMed PubMed Central

[36] Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718–25.10.1093/eurjhf/hfr047Suche in Google Scholar PubMed

[37] Tolppanen H, Rivas-Lasarte M, Lassus J, Sadoune M, Gayat E, Pulkki K, et al. Combined measurement of soluble ST2 and amino-terminal Pro-B type natriuretic peptide provides early assessment of severity in cardiogenic shock complicating acute coronary syndrome. Crit Care Med. 2017;45:e666–e673.10.1097/CCM.0000000000002336Suche in Google Scholar PubMed

[38] Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol. 2015;115:48B–58B.10.1016/j.amjcard.2015.01.041Suche in Google Scholar PubMed

[39] Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180–7.10.1161/CIRCHEARTFAILURE.110.958223Suche in Google Scholar PubMed PubMed Central